BioAgilytix Announces the Creation of an Advisory Board

BioAgilytix, a leading provider of contract bioanalytical testing services, today announced the formation of an Advisory Board with deep scientific, commercial and regulatory expertise in the Biotechnology, Pharmaceutical and Contract Research industries.  The board held its first meeting this month under the chairmanship of Jim Datin, Chief Executive Officer of BioAgilytix Labs.

Board member Jack Barbut, CEO of NovImmune, notes that ”by 2018 it is projected 50% of the U.S. prescription drug market will consist of large-molecule therapeutics.  BioAgilytix, being a premiere niche player in this rapidly growing segment of drug development is primed to grow alongside this industry trend.  The creation of an Advisory Board is a vital step as BioAgilytix transitions from a small specialty provider to a mid-size CRO with broader capabilities and global locations.”

Jim Datin commented that ”the establishment of an advisory board is essential and is a first for BioAgilytix.  BioAgilytix’s greatest strength is in our scientific expertise and quality-focused approach.  The Advisory Board will provide inspiration and guidance for BioAgilytix on how to scale our business without sacrificing our core values.”

The Board will help BioAgilytix with strategic decision to expand globally with additional platforms to meet customer needs.

Composition of the BioAgilytix Advisory Board:

Jack Barbut, CEO, NovImmune

Kurt Brykman, Former Divisional President, PAREXEL International

Terry Herring, President, Mission Pharmaceuticals and Former President, Inventiv Health.

7 more seasoned executives from top contract research organizations (CROs) and biotechnology have also joined the advisory board.

About BioAgilytix Labs www.bioagilytix.com

BioAgilytix is a leading bioanalytical testing laboratory specializing in large-molecule bioanalysis.  Located in North Carolina’s Research Triangle, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development , validation, and sample analysis under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP.

Share This